U.S Physical Therapy EBITDA 2010-2024 | USPH

U.S Physical Therapy ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
U.S Physical Therapy Annual EBITDA
(Millions of US $)
2023 $86
2022 $81
2021 $82
2020 $63
2019 $78
2018 $70
2017 $64
2016 $58
2015 $55
2014 $53
2013 $44
2012 $44
2011 $37
2010 $39
2009 $34
U.S Physical Therapy Quarterly EBITDA
(Millions of US $)
2024-09-30 $19
2024-06-30 $24
2024-03-31 $19
2023-12-31 $21
2023-09-30 $20
2023-06-30 $24
2023-03-31 $21
2022-12-31 $20
2022-09-30 $19
2022-06-30 $24
2022-03-31 $19
2021-12-31 $20
2021-09-30 $20
2021-06-30 $25
2021-03-31 $18
2020-12-31 $21
2020-09-30 $23
2020-06-30 $13
2020-03-31 $7
2019-12-31 $18
2019-09-30 $19
2019-06-30 $22
2019-03-31 $18
2018-12-31 $17
2018-09-30 $18
2018-06-30 $19
2018-03-31 $16
2017-12-31 $16
2017-09-30 $15
2017-06-30 $18
2017-03-31 $15
2016-12-31 $14
2016-09-30 $14
2016-06-30 $17
2016-03-31 $14
2015-12-31 $15
2015-09-30 $14
2015-06-30 $15
2015-03-31 $11
2014-12-31 $13
2014-09-30 $13
2014-06-30 $16
2014-03-31 $11
2013-12-31 $11
2013-09-30 $11
2013-06-30 $12
2013-03-31 $10
2012-12-31 $10
2012-09-30 $11
2012-06-30 $12
2012-03-31 $11
2011-12-31 $5
2011-09-30 $10
2011-06-30 $12
2011-03-31 $10
2010-12-31 $9
2010-09-30 $10
2010-06-30 $11
2010-03-31 $8
2009-12-31 $8
2009-09-30 $9
2009-06-30 $10
2009-03-31 $8
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $1.362B $0.605B
U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh's clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company's growth, are structured like the de novo partnerships, with significant ownership retained by founders.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $19.525B 11.81
Quest Diagnostics (DGX) United States $17.124B 17.35
DaVita (DVA) United States $12.715B 16.44
Encompass Health (EHC) United States $9.488B 22.37
Chemed (CHE) United States $7.824B 24.05
Elanco Animal Health (ELAN) United States $5.873B 13.98
RadNet (RDNT) United States $5.431B 120.26
Option Care Health (OPCH) United States $3.882B 18.40
LifeStance Health (LFST) United States $2.789B 0.00
Amedisys (AMED) United States $2.789B 19.85
Addus HomeCare (ADUS) United States $2.337B 27.42
Astrana Health (ASTH) United States $1.883B 25.75
Pennant (PNTG) United States $0.925B 37.42
Aveanna Healthcare Holdings (AVAH) United States $0.854B 0.00
Atai Life Sciences (ATAI) Germany $0.206B 0.00
Bioqual (BIOQ) United States $0.059B 0.00
Daxor (DXR) United States $0.038B 0.00
Ontrak (OTRK) United States $0.006B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.006B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00
Psychemedics (PMD) United States $0.000B 0.00